Senolytic Combo Dasatinib and Quercetin Repairs Bone Loss in Diabetic Mice
D+Q senolytics reshaped gut microbiota and serum metabolites to reverse diabetic osteoporosis in mice, pointing toward a novel therapeutic avenue.
Summary
Researchers tested the senolytic combination of Dasatinib and Quercetin (D+Q) in a mouse model of type 2 diabetic osteoporosis (T2DOP). After 7 weeks of treatment, D+Q significantly improved bone microarchitecture, reduced body weight gain, and lowered blood glucose. Mechanistically, D+Q reshaped gut microbiota by increasing beneficial short-chain fatty acid (SCFA) producers such as Lachnospiraceae and Bacteroides while reducing pro-inflammatory Mucispirillum. Serum metabolomics revealed enhanced amino acid and SCFA metabolism alongside reduced cholesterol and triglycerides. Immunohistochemistry indicated that autophagy pathway activation—evidenced by increased LC3 and Beclin1 and decreased P62—may be a key mechanism. These findings suggest D+Q could be a viable multi-target strategy for managing T2DOP.
Detailed Summary
Type 2 diabetic osteoporosis (T2DOP) is a serious metabolic bone disorder in which chronic hyperglycemia, insulin resistance, and cellular senescence collectively impair bone quality and raise fracture risk—even when bone mineral density appears normal. Senescent cell accumulation is a hallmark of both type 2 diabetes and skeletal fragility, making senolytics an attractive therapeutic concept. The combination of Dasatinib (a tyrosine kinase inhibitor) and Quercetin (a flavonoid), collectively called D+Q, is one of the most clinically studied senolytic pairs, yet its impact specifically on T2DOP and the gut-bone axis had not been characterized.
To address this gap, researchers at Guangzhou University of Chinese Medicine established a T2DOP mouse model in male C57BL/6J mice using 4 weeks of high-fat diet followed by streptozotocin injections. Animals were divided into control, untreated T2DOP model, and D+Q-treated groups (n=6 per group), with D+Q administered by gavage for 7 weeks at 50 mg/kg each.
Micro-CT analysis of the femur showed that D+Q treatment significantly improved trabecular bone parameters—including bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N)—while reducing trabecular separation (Tb.Sp) and the structure model index (SMI) compared to untreated T2DOP mice. Histological staining confirmed reduced osteoclast activity (TRAcP staining) and improved bone marrow fat balance (H&E staining). Liver histology also showed reduced lipid accumulation. Body weight gain and fasting blood glucose were both significantly attenuated in the D+Q group.
16S rRNA gut microbiome sequencing revealed that D+Q substantially altered the composition of the gut microbiota. At the family level, beneficial SCFA-producing taxa—Lachnospiraceae and Bacteroides—were enriched, while the pro-inflammatory genus Mucispirillum was reduced. These shifts aligned with improved metabolic and bone outcomes. Serum LC-MS/MS metabolomics (PLS-DA analysis, VIP>1.0, p<0.05) identified significant upregulation of amino acid metabolism pathways and SCFA-related metabolites, alongside downregulation of cholesterol, triglycerides, and glycerophospholipids in D+Q-treated mice. SCFAs such as acetate and butyrate are known to inhibit osteoclastogenesis through FFAR2 signaling, providing a plausible mechanistic link between microbiome changes and bone protection.
Immunohistochemistry further revealed that D+Q activated autophagy in bone tissue, as indicated by increased LC3A/B and Beclin1 expression and decreased P62 accumulation—consistent with clearance of senescent and dysfunctional cells. The authors propose that restored autophagy flux is a central mechanism by which D+Q alleviates T2DOP, complementing its effects on the gut-metabolite axis. Together, these findings present D+Q as a multi-mechanistic intervention targeting senescence, gut dysbiosis, and metabolic dysfunction simultaneously in T2DOP.
Key Findings
- D+Q improved femoral trabecular bone microarchitecture (BV/TV, Tb.Th, Tb.N) in T2DOP mice after 7 weeks.
- D+Q increased gut SCFA producers (Lachnospiraceae, Bacteroides) and decreased pro-inflammatory Mucispirillum.
- Serum metabolomics showed enhanced amino acid and SCFA metabolism with reduced cholesterol and triglycerides.
- Autophagy markers LC3 and Beclin1 were upregulated and P62 reduced, suggesting senescent cell clearance.
- D+Q significantly attenuated weight gain and fasting blood glucose in the T2DOP mouse model.
Methodology
Male C57BL/6J mice (n=6/group) were fed a high-fat diet and injected with streptozotocin to induce T2DOP, then treated with D+Q (50 mg/kg each) by gavage for 7 weeks. Bone outcomes were assessed via micro-CT and histology; gut microbiota was profiled by 16S rRNA V3-V4 amplicon sequencing; serum metabolites were characterized by LC-MS/MS with PLS-DA analysis.
Study Limitations
The study used only male mice (n=6/group), limiting generalizability across sexes and to human T2DOP. The mouse model relies on STZ-induced diabetes, which may not fully recapitulate human T2DM pathophysiology. No human data are presented, and long-term safety or efficacy of D+Q for bone outcomes has not been established clinically.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.